{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T17:47:30Z","timestamp":1787593650975,"version":"build-2736575974"},"reference-count":41,"publisher":"American Diabetes Association","issue":"2","license":[{"start":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T00:00:00Z","timestamp":1630281600000},"content-version":"vor","delay-in-days":2783,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,2,1]]},"abstract":"<jats:p>Dipeptidyl peptidase-4 (DPP-4) inhibitors prevent degradation of incretin hormones (glucagon-like peptide 1 [GLP-1] and glucose-dependent insulinotropic polypeptide [GIP]), whereas metformin may increase GLP-1 levels. We examined, in a four-period crossover trial, the influence of metformin (2,000 mg\/day), sitagliptin (100 mg\/day), or their combination, on GLP-1 responses and on the incretin effect in 20 patients with type 2 diabetes, comparing an oral glucose challenge (75 g, day 5) and an \u201cisoglycemic\u201d intravenous glucose infusion (day 6). Fasting total GLP-1 was significantly increased by metformin and not changed by sitagliptin. After oral glucose, metformin increased and sitagliptin significantly decreased (by 53%) total GLP-1. Fasting and postload intact GLP-1 increased with sitagliptin but not with metformin. After oral glucose, only sitagliptin, but not metformin, significantly augmented insulin secretion, in monotherapy and as an add-on to metformin. The incretin effect was not changed numerically with any of the treatments. In conclusion, sitagliptin increased intact GLP-1 and GIP through DPP-4 inhibition but reduced total GLP-1 and GIP (feedback inhibition) without affecting the numerical contribution of the incretin effect. Insulin secretion with sitagliptin treatment was similarly stimulated with oral and \u201cisoglycemic\u201d intravenous glucose. This points to an important contribution of small changes in incretin concentrations within the basal range or to additional insulinotropic agents besides GLP mediating the antidiabetic effects of DPP-4 inhibition.<\/jats:p>","DOI":"10.2337\/db13-0805","type":"journal-article","created":{"date-parts":[[2013,11,2]],"date-time":"2013-11-02T01:18:34Z","timestamp":1383355114000},"page":"663-674","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":88,"title":["Effects of Sitagliptin and Metformin Treatment on Incretin Hormone and Insulin Secretory Responses to Oral and \u201cIsoglycemic\u201d Intravenous Glucose"],"prefix":"10.2337","volume":"63","author":[{"given":"Irfan","family":"Vardarli","sequence":"first","affiliation":[{"name":"Diabeteszentrum Bad Lauterberg, Bad Lauterberg im Harz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Arndt","sequence":"additional","affiliation":[{"name":"Diabeteszentrum Bad Lauterberg, Bad Lauterberg im Harz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn F.","family":"Deacon","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Panum Institute, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens J.","family":"Holst","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Panum Institute, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Nauck","sequence":"additional","affiliation":[{"name":"Diabeteszentrum Bad Lauterberg, Bad Lauterberg im Harz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2014,1,16]]},"reference":[{"key":"2022051610540812100_B1","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"2022051610540812100_B2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF02427280","article-title":"Reduced incretin effect in type 2 (non-insulin-dependent) diabetes","volume":"29","author":"Nauck","year":"1986","journal-title":"Diabetologia"},{"key":"2022051610540812100_B3","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/0026-0495(87)90153-3","article-title":"Effect of porcine gastric inhibitory polypeptide on \u03b2-cell function in type I and type II diabetes mellitus","volume":"36","author":"Krarup","year":"1987","journal-title":"Metabolism"},{"key":"2022051610540812100_B4","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1172\/JCI116186","article-title":"Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus","volume":"91","author":"Nauck","year":"1993","journal-title":"J Clin Invest"},{"key":"2022051610540812100_B5","doi-asserted-by":"crossref","first-page":"380","DOI":"10.2337\/diabetes.52.2.380","article-title":"The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects","volume":"52","author":"Kjems","year":"2003","journal-title":"Diabetes"},{"key":"2022051610540812100_B6","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/BF00401145","article-title":"Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients","volume":"36","author":"Nauck","year":"1993","journal-title":"Diabetologia"},{"key":"2022051610540812100_B7","first-page":"327","article-title":"Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients","volume":"81","author":"Willms","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2022051610540812100_B8","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1007\/s001250050613","article-title":"Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM","volume":"39","author":"Nauck","year":"1996","journal-title":"Diabetologia"},{"key":"2022051610540812100_B9"},{"key":"2022051610540812100_B10","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0014-2999(02)01434-6","article-title":"Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives","volume":"440","author":"Meier","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"2022051610540812100_B11","first-page":"4382","article-title":"A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans","volume":"86","author":"Verdich","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2022051610540812100_B12","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1046\/j.1365-2362.1997.1490691.x","article-title":"Glucagon-like peptide-1 (GLP-1): a trial of treatment in non-insulin-dependent diabetes mellitus","volume":"27","author":"Todd","year":"1997","journal-title":"Eur J Clin Invest"},{"key":"2022051610540812100_B13","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1172\/JCI115012","article-title":"Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine","volume":"87","author":"\u00d8rskov","year":"1991","journal-title":"J Clin Invest"},{"key":"2022051610540812100_B14","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1210\/jc.2002-021873","article-title":"Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus","volume":"88","author":"Vilsb\u00f8ll","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2022051610540812100_B15","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1210\/jc.2003-031907","article-title":"Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes","volume":"89","author":"Ahr\u00e9n","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2022051610540812100_B16","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0140-6736(87)91194-9","article-title":"Glucagon-like peptide-1 7-36: a physiological incretin in man","volume":"2","author":"Kreymann","year":"1987","journal-title":"Lancet"},{"key":"2022051610540812100_B17","first-page":"912","article-title":"Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations","volume":"76","author":"Nauck","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"2022051610540812100_B18"},{"key":"2022051610540812100_B19","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1210\/jc.2010-2178","article-title":"Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as \u201cisoglycemic\u201d intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes","volume":"96","author":"Vardarli","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2022051610540812100_B20","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1210\/jc.2012-1205","article-title":"Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes","volume":"97","author":"Muscelli","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2022051610540812100_B21","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1463-1326.2006.00704.x","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial","volume":"9","author":"Nauck","year":"2007","journal-title":"Diabetes Obes Metab"},{"key":"2022051610540812100_B22","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1463-1326.2008.00994.x","article-title":"Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy","volume":"11","author":"Ferrannini","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"2022051610540812100_B23"},{"key":"2022051610540812100_B24","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ejphar.2006.07.043","article-title":"Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1","volume":"547","author":"Green","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"2022051610540812100_B25"},{"key":"2022051610540812100_B26","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1006\/bbrc.2002.6607","article-title":"Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1","volume":"291","author":"Hinke","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"key":"2022051610540812100_B27","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/clpt.2010.184","article-title":"Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1","volume":"88","author":"Migoya","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"2022051610540812100_B28"},{"key":"2022051610540812100_B29","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0169-2607(96)01755-5","article-title":"ISEC: a program to calculate insulin secretion","volume":"50","author":"Hovorka","year":"1996","journal-title":"Comput Methods Programs Biomed"},{"key":"2022051610540812100_B30","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1210\/jcem-51-3-520","article-title":"Prehepatic insulin production in man: kinetic analysis using peripheral connecting peptide behavior","volume":"51","author":"Eaton","year":"1980","journal-title":"J Clin Endocrinol Metab"},{"key":"2022051610540812100_B31","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1172\/JCI112308","article-title":"Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients","volume":"77","author":"Polonsky","year":"1986","journal-title":"J Clin Invest"},{"key":"2022051610540812100_B32","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.2337\/db09-1253","article-title":"Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes","volume":"59","author":"Salehi","year":"2010","journal-title":"Diabetes"},{"key":"2022051610540812100_B33"},{"key":"2022051610540812100_B34","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1210\/en.2011-0286","article-title":"Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice","volume":"152","author":"Waget","year":"2011","journal-title":"Endocrinology"},{"key":"2022051610540812100_B35"},{"key":"2022051610540812100_B36"},{"key":"2022051610540812100_B37","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1677\/joe.0.1720355","article-title":"Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs","volume":"172","author":"Deacon","year":"2002","journal-title":"J Endocrinol"},{"key":"2022051610540812100_B38","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1210\/jc.2006-1932","article-title":"The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion","volume":"92","author":"El-Ouaghlidi","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2022051610540812100_B39","doi-asserted-by":"crossref","first-page":"4612","DOI":"10.1210\/jc.2006-1009","article-title":"Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes","volume":"91","author":"Herman","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2022051610540812100_B40","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.2337\/diab.44.9.1126","article-title":"Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects","volume":"44","author":"Deacon","year":"1995","journal-title":"Diabetes"},{"key":"2022051610540812100_B41","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1185\/03007990802705679","article-title":"Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study","volume":"25","author":"Williams-Herman","year":"2009","journal-title":"Curr Med Res Opin"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.org\/diabetes\/diabetes\/article-pdf\/63\/2\/663\/409946\/663.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/63\/2\/663\/409946\/663.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T16:37:21Z","timestamp":1667407041000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/63\/2\/663\/34141\/Effects-of-Sitagliptin-and-Metformin-Treatment-on"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,16]]},"references-count":41,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2014,1,16]]},"published-print":{"date-parts":[[2014,2,1]]}},"URL":"https:\/\/doi.org\/10.2337\/db13-0805","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,16]]}}}